<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008929</url>
  </required_header>
  <id_info>
    <org_study_id>HCC_ MG4101</org_study_id>
    <nct_id>NCT02008929</nct_id>
  </id_info>
  <brief_title>to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)</brief_title>
  <acronym>MG4101</acronym>
  <official_title>A Single Center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) in Hepatocellular Carcinoma After Curative Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see the safety and efficacy of injecting MG4101 as a secondary treatment after curative
      liver resection on the patient with advanced HCC who has high risk of recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To see the safety and efficacy of injecting MG4101(Ex vivo expanded allogeneic NK cell) as a
      secondary treatment after curative liver resection on the patient with advanced HCC who has
      high risk of recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival, DFS</measure>
    <time_frame>Disease free survival for 1year</time_frame>
    <description>As of Date for allocation to survival and recurrence of the incident or death from any cause is defined as. 1 year disease-free survival was calculated using Kaplan-Meier estimation and 95% confidence interval and median survival (median survival time) are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in tumor markers</measure>
    <time_frame>Changes in tumor markers. to be specific, alpha-fetoprotein(AFP), protein induced by vitamin K absence- II(PIVKA-II)</time_frame>
    <description>Basaline(V2) at each visit compared (V6, V8, V9, V10) with respect to variation in average by descriptive statistics (mean, standard deviation, median, minimum, maximum) and presented, in comparison to the group in order Paired t-test or the Wilcoxon's signed rank test for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, OS</measure>
    <time_frame>Overall survival, OS at the end point of clinical trial</time_frame>
    <description>As of Date for allocation to survival, and the incident was defined as death from any cause.
1 year overall survival was calculated using Kaplan-Meier estimation and 95% confidence interval and median survival (median survival time) are presented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>MG4101</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ex vivo expanded allogeneic NK cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG4101</intervention_name>
    <description>Ex vivo expanded allogeneic NK cell</description>
    <arm_group_label>MG4101</arm_group_label>
    <other_name>NK cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Under the age of 20 to 69 years of age

          2. Child-pugh class A

          3. After curative liver resection, diagnosed hepatocellular carcinoma

          4. Modified UICC staging : stage 3

          5. the women who is childbearing age, agree to maintain adequate contraception measure
             during clinical trial period.

          6. Agreed to participate in this clinical trial, agree to the subject person or legal
             representative who agrees in writing

        Exclusion Criteria:

          1. Less than 20 years old, 70 years old or older

          2. Metastasis of hepatocellular carcinoma with external parties surgery

          3. who had Rupture of hepatocellular carcinoma (HCC)

          4. Hepatocellular carcinoma treated with radiofrequency surgery therapeutics
             (Radiofrequency ablation, RFA), the carotid artery chemical embolization
             (Transarterial chemoembolization, TACE), underwent radiation therapy, such as topical
             therapeutics

          5. suspected serious infection

          6. Who have severe cardiovascular disease (coronary artery disease requiring treatment,
             heart failure, arrhythmias, myocardial infarction, etc.)

          7. Pregnant, planning a pregnancy or breast-feeding women

          8. Autoimmune Disease

          9. Those who Latest within four weeks of administration of systemic steroids (However,
             inhalation, intranasal corticosteroids and topical administration of corticosteroids
             and short-time administration of a blood transfusion, if such reasons are excluded)

         10. Latest within four weeks of taking immunosuppressive drugs such as Cyclosporine A

         11. Within the last 5 years diagnosed with liver cancer and other malignancies

         12. Investigator did not complete or the effectiveness or safety of pharmaceutical
             products of this clinical trial evaluation for any medical condition that can
             interfere with characters judged
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Won Joh, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2013</study_first_submitted>
  <study_first_submitted_qc>December 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>JAE WON JOH</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>NKCELL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

